---
document_datetime: 2025-04-28 14:56:04
document_pages: 28
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eliquis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: eliquis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 17.5063664
conversion_datetime: 2025-12-27 17:31:07.617918
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Eliquis

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                   |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0096              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 18/04/2025                          |                                             | SmPC, Labelling and PL           |                                                                                                                                                                           |
| PSUSA/226/2 02405    | Periodic Safety Update EU Single assessment - apixaban                                         | 30/01/2025                          | 28/03/2025                                  | SmPC and PL                      | Anticoagulant-related nephropathy (ARN): In view of available data including 6 relevant, biopsy-confirmed cases of ARN indicating a possible association with apixaban, a |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  | pharmacological class effect (ARN is already listed for other DOACs rivaroxaban and edoxaban), and pathophysiological plausibility, the PRAC considers a causal relationship between apixaban and ARN is at least a reasonable possibility. The PRAC concludes that the product information of products containing apixaban should be amended accordingly.   |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0095  | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/08/2024 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                              |
| IB/0093  | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/07/2024 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                              |
| X/0089/G | This was an application for a group of variations. Extension application to: 1) Introduce a new pharmaceutical form (granules in single-dose container) associated with a new strength (0.15 mg). 2) Introduce a new pharmaceutical form (coated granules in sachet) associated with 3 new strengths (0.5 mg, 1.5 mg and 2 mg) Extension of indication to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to less than 18 years of age for Eliquis (all strengths), based on a pre-specified interim analysis from Study CV185325; this is an open-label, multi-centre, randomized, active controlled trial to provide PK data | 30/05/2024 | 26/07/2024 | SmPC, Annex II, Labelling and PL | Please refer to the Assessment Report Eliquis EMEA-H-C- 002148-X-0089-G                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | on anti-Xa activity to support the extrapolation of efficacy to children, to evaluate safety and efficacy of apixaban in children who require anticoagulation for a venous thromboembolism; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPCs are updated. The Package Leaflet and Annex II are updated in accordance. Version 21.3 of the RMP has also been submitted. Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form Annex I_2.(c) Change or addition of a new strength/potency Annex I_2.(d) Change or addition of a new pharmaceutical form C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |                 | and data modification   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------|
| IAIN/0092 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/03/2024 | 06/05/2024 | Annex II and PL |                         |
| IB/0090   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/11/2023 | n/a        |                 |                         |
| IA/0091/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/09/2023 | n/a        |                 |                         |

<div style=\"page-break-after: always\"></div>

|             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                   |            |            |                 |                                                                                                                                                   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0088     | Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information in the paediatric population based on results of the paediatric studies performed in compliance with the paediatric investigation plan (PIP), including studies CV185155 and CV185362. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 25/05/2023 | 06/05/2024 | SmPC            | Please refer to Scientific Discussion 'Eliquis-H-C-002148-II- 0088' For more information, please refer to the Summary of Product Characteristics. |
| IAIN/0087/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging    | 08/09/2022 | 31/03/2023 | Annex II and PL |                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|             | site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                 |                       |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------|
| IA/0086/G   | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - | 04/07/2022 | n/a        |                 | Introduction of a new |
| IAIN/0085/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                           | 16/02/2022 | 31/03/2023 | Annex II and PL |                       |

<div style=\"page-break-after: always\"></div>

|                   | finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                          |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/226/2 02105 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                                                                                                                                                                                                                        | 16/12/2021 | 16/02/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/226/202105. |
| IA/0084           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                  | 30/09/2021 | n/a        |             |                                                                                                                                          |
| IB/0082/G         | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products             | 07/05/2021 | n/a        |             |                                                                                                                                          |
| II/0080           | Update of section 4.4 of the SmPC in order to update the existing warning regarding patient with active cancer in line with the final results of the study CARAVAGGIO (NCT03045406), which is a randomized open-label non-inferiority clinical trial assessing apixaban for the treatment of acute proximal DVT and/or PE in ambulatory patients with active cancer or history of cancer. In addition, the MAH took the opportunity to make a | 15/04/2021 | 16/02/2022 | SmPC        |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                   | the list of local representatives from the package leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                  |                                                                                                                                                                                                                                                                       |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/226/2 02005 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                          | 28/01/2021 | 31/03/2021 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/226/202005.                                                                                                                              |
| IA/0081           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                            | 10/02/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| R/0077            | Renewal of the marketing authorisation.                                                                                                                                         | 12/11/2020 | 11/01/2021 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Eliquis in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0079           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                | 15/12/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                       |
| N/0078            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                | 07/10/2020 | 11/01/2021 | PL                               |                                                                                                                                                                                                                                                                       |
| IB/0075           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                  | 03/08/2020 | 11/01/2021 | SmPC                             |                                                                                                                                                                                                                                                                       |
| IAIN/0074/G       | This was an application for a group of variations.                                                                                                                              | 23/04/2020 | 11/01/2021 | Annex II and                     |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                               |            |            | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0064           | Update of sections 4.2, 4.4, 4.5 and 5.1 of the SmPC in order to update the safety information based on the final results from study CV185316 (AUGUSTUS), an open-label, randomised, controlled clinical trial to evaluate the safety of apixaban in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/03/2020 | 11/01/2021 | SmPC | A study in patients with non-valvular atrial fibrillation who had acute coronary syndrome and/or had undergone percutaneous coronary showed that acetylsalicylic acid significantly increased the risk of major or clinically relevant non-major (CRNM) bleeding when added to anticoagulation (either apixaban or Vitamin K antagonist) on top of a background therapy with a P2Y12 inhibitor. Apixaban was superior to Vitamin K antagonist for adjudicated major and CRNM bleeding events. |
| IB/0073/G         | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                | 20/03/2020 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/226/2 01905 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                                                                                                                                                                                                                                                          | 12/12/2019 | 17/02/2020 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                            |            |            |       | PSUSA/226/201905.                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------|-----------------------------------------------------------|
| IA/0072   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                           | 28/01/2020 | n/a        |       |                                                           |
| IAIN/0071 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                         | 16/01/2020 | n/a        |       |                                                           |
| N/0068    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 20/12/2019 | 11/01/2021 | PL    |                                                           |
| IAIN/0070 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                             | 16/12/2019 | n/a        |       |                                                           |
| IA/0069   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 03/12/2019 | n/a        |       |                                                           |
| IAIN/0067 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                             | 20/11/2019 | n/a        |       |                                                           |
| II/0063   | Update of sections 4.4 and 4.9 of the SmPC in order                                                                                                                                                                                        | 03/10/2019 | 17/02/2020 | SmPC, | For situations when reversal of anticoagulation is needed |

<div style=\"page-break-after: always\"></div>

|           | to reflect the availability of a reversal agent for apixaban following the recent approval of andexanet alfa in the EU; the Package Leaflet and Labelling are updated accordingly. The RMP version 20.1 has also been submitted, with updates due to the availability of a reversal agent and implement the revised GVP template Rev.2. As a result, the list of safety concerns has been updated and a number of safety concerns listed as missing information have been reclassified and have been removed from the RMP. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to update the information in the SmPC and Package Leaflet in accordance with the most recent guidance on labelling of excipients of medicinal products for human use. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |     | Labelling and PL   | due to life-threatening or uncontrolled bleeding, a reversal agent for the anti- factor Xa activity of apixaban is available.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|---------------------------------------------------------------------------------------------------------------------------------|
| IA/0066/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/08/2019 | n/a |                    |                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                   | B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised          |            |            |                        |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0062           | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                               | 01/07/2019 | 17/02/2020 | SmPC and PL            |                                   |
| II/0059           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                            | 29/05/2019 | 01/07/2019 | SmPC and PL            |                                   |
| IAIN/0061         | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 07/06/2019 | 17/02/2020 | SmPC and PL            |                                   |
| IAIN/0060         | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                   | 07/03/2019 | 02/04/2019 | SmPC, Labelling and PL |                                   |
| PSUSA/226/2 01805 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                       | 29/11/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0058           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 15/10/2018 | n/a        |                        |                                   |
| IAIN/0056         | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                               | 03/08/2018 | 02/04/2019 | SmPC and PL            |                                   |

<div style=\"page-break-after: always\"></div>

|         | Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050 | Update of sections 4.2 and 5.1 of the SmPC in order to update the posology, efficacy and safety information for patients undergoing cardioversion based on the final results from the post-authorisation efficacy study EMANATE. The package leaflet and the RMP (version 19.0) are updated accordingly. In addition, the marketing authorisation holder (MAH) took the opportunity to update their address in the product information and the list of local representative in the package leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/04/2018 | 31/05/2018 | SmPC, Labelling and PL | Posology for patients undergoing cardioversion: Apixaban can be initiated or continued in non-valvular atrial fibrillation (NVAF) patients who may require cardioversion. For patients not previously treated with anticoagulants, at least 5 doses of apixaban 5 mg twice daily (2.5 mg twice daily in patients who qualify for a dose reduction (see recommendation for Dose reduction and Renal impairment)) should be given before cardioversion to ensure adequate anticoagulation. If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily. The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see recommendation for Dose reduction and Renal impairment). The administration of the loading dose should be given at least 2 hours before cardioversion. Confirmation should be sought prior to cardioversion that the patient has taken apixaban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account. Clinical efficacy and safety information for patients undergoing cardioversion: EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant na√Øve or pre- treated less than 48 hours, and scheduled for cardioversion for NVAF. Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                         |            |            |             | events. Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients if earlier cardioversion was required. In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5 mg dose). There were no strokes (0%) in the apixaban group (n= 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64). All cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group. No systemic embolism events were reported. Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group. This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0051   | Update of section 4.8 of the SmPC in order to reflect all adverse drug reactions for all indications with the correct calculated frequency based on clinical trials data. The package leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/05/2018 | 02/04/2019 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0055/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                      | 02/05/2018 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor to an approved test procedure   |            |     | changes   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IAIN/0054/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                            | 16/04/2018 | n/a |           |
| IA/0053     | B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/03/2018 | n/a |           |

<div style=\"page-break-after: always\"></div>

| IA/0052           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                | 05/02/2018   | n/a   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0048           | Submission of the final report from study (B0661073) listed as a category 4 study in the RMP. This is a non-interventional post-authorisation safety study (PASS) of the utilisation patterns of apixaban in Denmark. In addition, a revised RMP (version 18.0) is submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 30/11/2017   | n/a   | The drug utilisation study (DUS) (B0661073) is a descriptive, retrospective, cross-sectional study that uses electronic healthcare data from the Danish national registries to describe the utilisation patterns of apixaban in Denmark. The study was conducted to estimate the proportion of apaxiban users in the outpatient settings who received the drug for the approved indications at the time of the study, and to describe the characteristics of patients who were prescribed apixaban for on-label or off-label indications. The results of this study indicated that apixaban was mostly (82.6%) used for on-label indications, with the majority of patients using apixaban for non- valvular atrial fibrillation (NVAF). The proportion of on-label apixaban use reported was similar to that of a previous Swedish DUS study (86.4% on-label), and to the proportion on-label use reported in the literature for other non-vitamin K oral anticoagulants (NOACs) (80-90% on-label use). Off- label use was found in nearly 11% of patients. The proportion of off-label use reported was comparable to that reported in previous similar DUS study in Sweden (7.7% off-label use). These results did not warrant an update of the product information. |
| PSUSA/226/2 01705 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                                                                                                                                                                                                      | 30/11/2017   | n/a   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| II/0049/G   | This was an application for a group of variations. B.II.b.1.d - Replacement or addition of a manufacturing site for the FP - Site which requires an initial or product specific inspection B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 16/11/2017   | n/a        |                    |                                                                                                                                                                                                                    |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0047     | Update of section 4.5 of the SmPC to include clarithromycin as one of the active substances which are not considered strong inhibitors of both CYP3A4 and P-gp and which are expected to increase apixaban plasma concentration to a lesser extent based on the final results from study CV185547. The final study report of study CV185547 (an open-label, non-randomised, single-sequence, crossover study in healthy subjects to determine the effect of multiple- dose clarithromycin on the single-dose pharmacokinetics of apixaban) is also submitted. In addition, the MAH took the opportunity to make some corrections in the SmPC and to update the labelling in line with the latest QRD template version 10.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 19/10/2017   | 31/05/2018 | SmPC and Labelling | Clarithromycin (500 mg, twice a day), an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3- fold increase in mean apixaban AUC and Cmax, respectively. No dose adjustment is required. |
| II/0043     | Submission of the final report from study (CV185- 365) listed as a category 3 study in the RMP. This is                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/09/2017   | n/a        |                    | The results of the PASS CV185-365 suggest that use of the risk minimisation tools appears to have positive impact                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                   | a post authorisation safety study which evaluates the effectiveness of Eliquis (apixaban) risk minimisation tools in the European Economic Area countries. A RMP (version 17.0) has also been submitted to reflect the completion of the study CV185-365. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                        | upon knowledge, comprehension, and behaviour among health care professionals and patients/caregivers regarding Eliquis treatment and associated bleeding risk. Although distribution and utilisation were not optimal, they are consistent with findings from similar effectiveness evaluation studies of risk minimisation tools. At present, the MAH does not propose any modifications to the content of the risk minimisation tools. The results are consistent with study objectives and support the effectiveness of the risk minisation tools for their intended purpose.   |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0044/G         | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                      | 09/08/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0045           | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                                | 17/07/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0042           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                    | 10/04/2017 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/226/2 01605 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                                                                                                                                                                                    | 15/12/2016 | 16/02/2017 | SmPC, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/226/201605.                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IAIN/0041/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                          | 08/12/2016   | 16/02/2017   | Annex II and PL   |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|
| II/0040       | Submission of the final study report of the AEGEAN study (CV185-220) which assess the education and guidance programme for Eliquis (apixaban) adherence in non-valvular atrial fibrillation patients. The updated risk management plan is also submitted to reflect the results of the study. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 13/10/2016   | n/a          |                   |
| II/0037/G     | This was an application for a group of variations. Submission of final study reports of two drug utilisation studies (DUS) in Sweden (Study B0661017) and in the Netherlands (Study B0661018) to fulfil post-approval measures listed in                                                                                                                                                                                                    | 15/09/2016   | n/a          |                   |

<div style=\"page-break-after: always\"></div>

|           | the risk management plan (RMP) which has also been submitted. The RMP has been updated to reflect the data from the two completed post- authorisation safety studies examining the utilisation pattern of apixaban in Sweden and in the Netherlands, to reflect ongoing DUS in Denmark (Study B0661073), to reflect updated approved SmPC with regard to administration as a crushed tablet (EMEA/H/C/002148/II/030) and prothrombin complex concentrates (EMEA/H/C/002148/II/029), and minor updates to various postmarketing commitment studies. The group of variations leads to amendments to the Risk Management Plan (RMP). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0038/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/07/2016 | n/a |

<div style=\"page-break-after: always\"></div>

|                   | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0036            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                            | 23/03/2016 | 16/02/2017 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0035           | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                        | 25/02/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0034            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                     | 19/11/2015 | 14/01/2016 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP was of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Eliquis continues to be favourable. The CHMP was of the opinion that an additional five-year renewal is required, on the basis of pharmacovigilance grounds. |
| PSUSA/226/2 01505 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                                                                                                                      | 03/12/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0030           | Update of sections 4.2 and 5.2 of the SmPC for Eliquis 2.5 mg and 5 mg film-coated tablets, to provide recommendations regarding the use of alternative methods of administration of apixaban tablets, based on the results from clinical                                                                                                   | 24/09/2015 | 14/01/2016 | SmPC and PL                      | For patients who are unable to swallow whole tablets, Eliquis tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally. Alternatively, Eliquis tablets may be crushed and                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | pharmacology studies CV185292 and CV185111. The Package Leaflet has been updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                    |            |            |             | suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube. Crushed Eliquis tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 20% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets. The reduction in exposure is not considered clinically relevant. Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose. Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029 | Update of sections 4.9 and 5.1 of the SmPC based on the study results from study CV185156 evaluating the ability of prothrombin complex concentrates (PCCs) to reverse the anticoagulant effect of apixaban in healthy subjects. The provision of the study report addresses the post approval measure MEA 016.1. In addition, the MAH took the opportunity to make minor editorial changes in the | 17/09/2015 | 14/01/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                      |            |            |             |                                                                                                                                          |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/226/2 01411 | Periodic Safety Update EU Single assessment - apixaban                                                                                                                                                                                                                                                 | 25/06/2015 | 20/08/2015 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/226/201411. |
| N/0032            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                       | 21/07/2015 | 14/01/2016 | PL          |                                                                                                                                          |
| IA/0031           | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                           | 29/05/2015 | n/a        |             |                                                                                                                                          |
| N/0026            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                       | 26/02/2015 | 20/08/2015 | Labelling   |                                                                                                                                          |
| PSUV/0022         | Periodic Safety Update                                                                                                                                                                                                                                                                                 | 04/12/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                        |
| IA/0024           | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                           | 03/12/2014 | n/a        |             |                                                                                                                                          |
| IA/0023/G         | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name | 30/10/2014 | n/a        |             |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|           | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                        |            |            |                                  |                                                                                                                                                                                                                                                                                                            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0021   | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                         | 12/08/2014 | n/a        |                                  |                                                                                                                                                                                                                                                                                                            |
| II/0014/G | This was an application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 26/06/2014 | 28/07/2014 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                            |
| N/0020    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                     | 12/06/2014 | 28/07/2014 | PL                               |                                                                                                                                                                                                                                                                                                            |
| PSUV/0018 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                               | 12/06/2014 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                          |
| II/0017   | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                    | 25/04/2014 | 28/07/2014 | SmPC                             | Update section 4.4 and 5.1 to update the Summary of Product Characteristics (SmPC) as follows: ‚Ä¢Section 4.4: to replace the term 'Rotachrom anti-FXa assay' with 'a calibrated quantitative anti-FXa assay' ‚Ä¢Section 5.1: to include the apixaban plasma concentration data (ng/mL) along with the already |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                     |            |            |                                  | approved anti-Xa activity data (IU/mL). The application is based on a study report study report testing 4 different chromogenic anti-FXa assays: (Rotachrom Heparin Assay , Liquid Anti-Xa Assay, Coamatic Heparin Assay and Technochrom Anti-Xa Assay.                                                                                                                                                                                                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016   | Update of sections 4.2 and 4.4 of the SmPC C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                        | 25/04/2014 | 28/07/2014 | SmPC                             | The applicant submited a sub-analysis from the ARSITOTLE study in patients who have undergone cardioversion (743 cardioversions in 540 patients). The incidence of systemic embolism, stroke, death, major bleedings and myocardial infarctions are comparable in the apixaban and the warfarin administered groups. Therefore in this variation a recommendation in section 4.2, that patients undergoing cardioversion can be maintained on apixaban, with a cross reference in section 4.4 are introduced. |
| IB/0019   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 16/04/2014 | 28/07/2014 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0015   | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                      | 26/11/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0011/G | This was an application for a group of variations. Amendments to the Summary of Product Characteristics, annex II, labelling and Package leaflet.                                                   | 19/09/2013 | 15/11/2013 | SmPC, Annex II, Labelling and PL | Update of sections 4.4, 4.9 and 5.2 of the SmPC following routine assessment of the Company Core Data Sheet (CCDS) and submission of a final study report in special populations. The proposed labelling revisions provide additional clarity that apixaban should not be used in patients with prosthetic heart valves and information in                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            |      | subjects with End Stage Renal Disease. This update - includes a recommendation that apixaban should not be used in patients with prosthetic heart valves (section 4.4) following a routine assessment of the Company Core Data Sheet (CCDS). - provides updated information in sections 4.9 and 5.2 following results of a special population study: 'Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Subjects on Haemodialysis' (CV185087). The Package Leaflet was proposed to be updated accordingly. Furthermore, the MAH took this opportunity to bring the PI in line with the latest QRD template version 9. Additionally, correction of some errors has been implemented such as the addition of Haemoptysis as   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0012 | Periodic Safety Update                                                                                                                                                                                                                                                                                          | 27/06/2013 | 26/08/2013 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0012.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| N/0013    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                | 23/08/2013 | 15/11/2013 | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0010/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved                                                            | 05/08/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch   |            |            |      | size   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------|
| IA/0009   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/04/2013 | n/a        |      |        |
| IA/0008   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/02/2013 | 26/08/2013 | SmPC |        |
| IAIN/0007 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/12/2012 | n/a        |      |        |

<div style=\"page-break-after: always\"></div>

| X/0004/G   | application for a group of variations. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Annex I_2.(c) Change or addition of a new strength/potency B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside approved pack sizes   | 20/09/2012   | 19/11/2012   | SmPC, Annex II, Labelling and PL   | This was an the range of the currently   |
|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|------------------------------------------|
| N/0006     | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                            | 30/03/2012   | 19/11/2012   | PL                                 |                                          |
| IA/0005    | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                                                                                                                                                  | 26/10/2011   | n/a          |                                    |                                          |
| II/0003/G  | This was an application for a group of variations. To register a NIR method for releasing apixaban tablets 2.5 mg (real time release testing, RTRT) at the currently approved finished product manufacturing site To register a second finished product manufacturing site for apixaban tablets 2.5 mg and NIR method for releasing                                                                         | 20/10/2011   | 20/10/2011   |                                    | To register the same                     |

<div style=\"page-break-after: always\"></div>

|         | apixaban tablets 2.5 mg (RTRT) at the second finished product manufacturing site B.II.d.3 - Variations related to the introduction of real-time release or parametric release in the manufacture of the finished product B.II.d.3 - Variations related to the introduction of real-time release or parametric release in the manufacture of the finished product B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products   |            |     |           |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IB/0002 | B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/09/2011 | n/a |           |
|         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                             | 04/07/2011 | n/a | IA/0001/G |